A pilot study of LumiThera’s Valeda Light Delivery System, a photobiomodulation (PBM) device, for the treatment of dry age-related macular degeneration (AMD) has demonstrated significant improvements in visual acuity.
The University of Auckland School of Optometry and Vision Science’s (SOVS’) Community Spectacle Scheme has received two significant donations, ensuring more New Zealanders can access glasses.
Glaukos has filed a supplemental pre-market approval application with the US Food and Drug Administration (FDA) for its iStent Infinite trabecular micro-bypass system.
Australia’s Young Optometrists (YO) association has challenged the Australian Pharmaceutical Formulary’s (APF’s) regulatory changes to the manufacturing and supply of compounded eye drops, which it
Patient complaints over compounded atropine eye drops are on the rise in New South Wales, with one patient lodging a grievance with the Australian Health Practitioner Regulation Agency (AHPRA) after
In a report published in the American Journal of Ophthalmology, a team of US researchers have shown that patients with ocular hypertension may benefit from cataract surgery. “Studies suggest that
Building on the achievements of Vision 2020, the International Agency for the Prevention of Blindness (IAPB) has released a new 10-year strategy: 2030 In Sight: Ending Avoidable Sight Loss. The plan
An open letter encouraging New Zealanders to get vaccinated against Covid-19 has been signed by more than 5,000 Aotearoa New Zealand doctors. The Royal Australian and New Zealand College of
An evaluation of the UK’s Covid-19 Urgent Eyecare Service (CUES) found it delivered a high level of primary care alongside a reduction in emergency eyecare department (EED) cases. Primary
The Independent Optometry Group (IOG) has welcomed Matthews Eyewear Eyecare into the fold, increasing its shareholding membership from 53 to 70 practices nationwide.
An Austrian study of short-term treatment deferral for exudative neovascular age-related macular degeneration (nAMD) has found its negative impact on visual acuity was sustained after one year.
A UK-wide study has shown that a new, safe and cost-saving surveillance pathway for people with stable diabetic eye disease is freeing up ophthalmologists to treat people requiring urgent care. The